Document:

First Amendment to Employment Agreement with Gerald L. Brickey

 Exhibit 10.1 
 FIRST AMENDMENT TO 
 EMPLOYMENT AGREEMENT 
 FOR 
 GERALD L. BRICKEY

 This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT FOR GERALD BRICKEY (“Agreement”), dated effective as of March 26, 2008, is
by and between COWLITZ BANCORPORATION, a Washington corporation (the “Company”), Cowlitz Bank, a Washington banking corporation (the “Bank”) (hereinafter the Company and the Bank are collectively referred to as the
“Employer”), and GERALD L. BRICKEY (“Executive”). 
 1. Amendments to Employment Agreement. The following
provisions of the Employment Agreement for Gerald L. Brickey dated effective as of December 28, 2005 (the “Employment Agreement”) are amended as set forth below: 
  

	 	a.	Section 7 of the Employment Agreement is amended to read as follows: 

 “7. “Good Reason”. 
 7.1 Good Reason for Executive’s resignation means
(i) any one or more of the conditions set forth in 7.2(a) through (d) exists without Executive’s consent, (ii) Executive provides notice to the Company of the existence of the condition within 90 days of the initial existence of
the condition, (iii) the Company has a 30-day following receipt of such notice to remedy the condition and fails to do so, and (iv) the Executive resigns within twelve months of such event occurring. 
 7.2 Conditions for “Good Reason” termination by Executive are as follows: 
  

	 	(a)	A material diminution in the Executive’s base compensation; 

  

	 	(b)	A material diminution in the Executive’s authority, duties, or responsibilities 

  

	 	(c)	A material change in the geographic location at which the Executive must perform the services under this Agreement; or 

  

	 	(d)	A material diminution in the authority, duties, or responsibilities of the supervisor to whom the Executive is required to report.” 

  

	 	b.	Section 8(b) of the Employment Agreement is amended to read as follows: 

  

	 	“(b)	 Without Cause of Good Reason. If Executive’s employment is terminated by Employer without Cause, or by Executive for Good Reason, the Bank will pay
Executive a severance benefit equal to twelve (12) months of Base Salary, based on the highest Base Salary paid to Executive in the preceding twelve months (the “Severance Benefit”), subject to statutory payroll deductions. The
Severance Benefit will be paid in installments over twelve months, starting the month following termination, in accordance with Employer’s standard payroll procedures. Receipt of the Severance Benefit is conditioned on Executive having executed
the Separation Agreement in substantially the form attached hereto as Exhibit A and the revocation period having expired without Executive having revoked the Separation Agreement. Receipt and continued receipt of the Severance benefit is
further conditioned on Executive not being in violation of 

	 	 
any material term of this Agreement or in violation of any material term of the Separation Agreement.” 

  

	 	c.	Section 8(d) of the Employment Agreement is amended to read as follows: 

  

	 	“(d)	Termination Related to Change in Control. A “Change in Control” occurs if: 

 (i) the Company merges or consolidates with another corporation and as a result less than 50% of the combined voting power of the resulting corporation
immediately after the merger or consolidation is held by persons who were the holders of the Company’s voting securities immediately before the merger or consolidation; 
 (ii) any person, entity, or group of persons or entities, other than through merger or consolidation, acquires a majority of the Company’s
outstanding stock or substantially all of the Company’s assets; or 
 (iii) a majority of the Company’s Board of Directors is
removed from office by a vote of the Company’s shareholders over the recommendation of the Board. 
 After announcement of a proposed
Change in Control and for a period continuing for two years following a Change in Control, in the event Employer terminates Executive’s employment without Cause or Executive provides notice of the existence of a Good Reason, as defined in
Section 7.2, within such two-year period (and ultimately terminates his employment for such Good Reason whether within such two-year period or subsequently following the notice and cure period set forth in Section 7.1), instead of
receiving the Severance Benefit set forth in Section 8(b) above, Executive shall receive (i) 24 months of Base Salary, based on Executive’s highest Base Salary in the two years preceding termination, (ii) an amount equal to two
times the Executive’s highest annual bonus paid in the two years preceding termination, and (iii) continuing insurance benefits for the Executive and dependents substantially similar to benefits received immediately prior to the Change in
Control and with the same contribution rate towards the premium applicable at the Date of Termination or at the date of Change in Control, if greater, for 24 months (collectively the “Change in Control Benefit”). If the Employer benefit
plans do not permit continued participation by the Executive following termination of employment, Employer shall include in the lump sum payment of the Change in Control Benefit an amount equal to the premiums (estimated in good faith by Employer)
that Employer would have paid under such benefit plans for Executive’s continued participation for a 2-year period. Receipt of the Change in Control Benefit is conditioned on Executive having executed the Separation Agreement in substantially
the form attached hereto as Exhibit A and the revocation period having expired without Executive having revoked the Separation Agreement. The cash Change in Control Benefit shall be paid in a lump sum upon Employer’s receipt of the
Executive’s Separation Agreement and the revocation period having expired without Executive having revoked the Separation Agreement. Receipt of the Change in Control Benefit is further conditioned on Executive not being in violation of any
material term of this Agreement or in violation of any material term of the Separation Agreement. 
  

	 	d.	Section 8(h) is added to the Employment Agreement as follows: 

  

	 	“(h)	 409A. Notwithstanding any provision of this Agreement to the contrary, if, at the time of Executive’s “separation of service” with the
Company, he is a “specified employee” as such terms are defined in Section 409A of the Internal Revenue Code and regulations promulgated thereunder, and one or more of the payments or benefits received or to be received by Executive
pursuant to this Agreement would constitute “deferred compensation” subject to Section 409A, no such payment or 

	 	 
benefit will be provided under this Agreement until the earlier of: (a) the date that is six (6) months following Executive’s termination of
employment with the Company or (b) the Executive’s death, unless the payment or distribution is exempt from the application of Section 409A. In the event any of Executive’s benefits that are paid in installments under this
Agreement are subject to the six-month delay set forth in this Section 8(h), the first installment payment shall be made in the seventh month following termination of employment and shall equal the aggregate installment payments Executive would
have received during the first six months plus the payment Executive is otherwise entitled to receive for the seventh month. 

 2. Except as specifically set forth herein, the Employment Agreement as previously executed shall continue in full force and effect as written. 
 3. ADVICE OF COUNSEL. Executive acknowledges that, in executing this Agreement, Executive has had the opportunity to seek the advice of independent legal counsel, and has read and understood all of the terms
and provisions of this Agreement. This Agreement shall not be construed against any party be reason of the drafting or preparation hereof. 
 IN WITNESS WHEREOF, the parties have signed this Agreement effective on the day and year first above written. 
 EXECUTIVE: 
  

	
	/S/ Gerald L. Brickey
	Gerald L. Brickey

 COWLITZ BANCORPORATION 
  

			
	By:	 	/S/ Richard J. Fitzpatrick
		 	Richard J. Fitzpatrick, President and CEO

 COWLITZ BANK 
  

			
	By:	 	/S/ Richard J. Fitzpatrick
		 	Richard J. Fitzpatrick, President and CEO

 Exhibit A 
 EMPLOYMENT SEPARATION AGREEMENT AND RELEASE OF CLAIMS 
 This is a confidential agreement (this
“Separation Agreement”) between you, Gerald L. Brickey, and us, Cowlitz Bancorporation and Cowlitz Bank (collectively, “Employer”). This Separation Agreement is dated for reference purposes
                    , 20        , which is the date we delivered this Separation Agreement to
you for your consideration. 
 1. Termination of Employment. Your employment terminates [or was terminated] on
                    , 20         (the “Separation Date”). 
 2. Payments. In exchange for your agreeing to the release of claims and other terms in this Separation Agreement, we will pay you the Severance
Benefit specified in Section 8(b) or the Change in Control Benefit in Section 8(d), as appropriate, of the Agreement between you and Employer dated June 13, 2005 (the “Employment Agreement”). Such provisions of the
Employment Agreement are incorporated herein by reference. You acknowledge that we are not obligated to make these payments to you unless you comply with the material terms of the Employment Agreement and of this Separation Agreement. 
 3. COBRA Continuation Coverage. Your normal employee participation in the Bank’s group health coverage will terminate on the Separation Date.
Continuation of group health coverage thereafter will be made available to you and your dependents pursuant to federal law (COBRA). Continuation of group health coverage after the Separation Date is entirely at your expense, as provided under COBRA.

 4. Termination of Benefits. Except as provided in Section 3 above, your participation in all employee benefit plans and
programs ended on the Separation Date. Your rights under any pension benefit or other plans in which you may have participated will be determined in accordance with the written plan documents governing those plans. 
 5. Full Payment. You acknowledge having received full payment of all compensation of any kind (including wages, salary, vacation, sick leave,
commissions, bonuses and incentive compensation) that you earned as a result of your employment by us, except for the Severance Benefit or Change in Control Benefit, if applicable. 
 6. No Further Compensation. Any and all agreements to pay you bonuses or other incentive compensation are terminated. You understand and agree
that you have no right to receive any further payments for bonuses or other incentive compensation. We owe no further compensation or benefits of any kind, except as described in Section 2 above. 
 7. Release of Claims. 
 (a) You hereby
release (i) Employer and its subsidiaries, affiliates, and benefit plans, (ii) each of Employer’s past and present shareholders, executives, directors, agents, employees, representatives, administrators, fiduciaries and attorneys, and
(iii) the predecessors, successors, transferees and assigns of each of the persons and entities described in this sentence, from any and all claims of any kind, known or unknown, that arose on or before the date you signed this Separation
Agreement. 
 (b) The claims you are releasing include, without limitation, claims of wrongful termination, claims of constructive discharge,
claims arising out of employment agreements, representations or policies 

 
related to your employment, claims arising under federal, state or local laws or ordinances prohibiting discrimination or harassment or requiring
accommodation on the basis of age, race, color, national origin, religion, sex, disability, marital status, sexual orientation or any other status, claims of failure to accommodate a disability or religious practice, claims for violation of public
policy, claims of retaliation, claims of failure to assist you in applying for future position openings, claims of failure to hire you for future position openings, claims for wages or compensation of any kind (including overtime claims), claims of
tortious interference with contract or expectancy, claims of fraud or negligent misrepresentation, claims of breach of privacy, defamation claims, claims of intentional or negligent infliction of emotional distress, claims of unfair labor practices,
claims arising out of any claimed right to stock or stock options, claims for attorneys’ fees or costs, and any other claims that are based on any legal obligations that arise out of or are related to your employment relationship with us.

 (c) You specifically waive any rights or claims that you may have under the Title 49 of the Revised Code of Washington, the Civil Rights
Act of 1964 (including Title VII of that Act), the Equal Pay Act of 1963, the Age Discrimination in Employment Act of 1967 (ADEA), the Americans with Disabilities Act of 1990 (ADA), the Fair Labor Standards Act of 1938 (FLSA), the Family and
Medical Leave Act of 1993 (FMLA), the Worker Adjustment and Retraining Notification Act (WARN), the Employee Retirement Income Security Act of 1974 (ERISA), the National Labor Relations Act (NLRA), and all similar federal, state and local laws.

 (d) You agree not to seek any personal recovery (of money damages, injunctive relief or otherwise) for the claims you are releasing in
this Separation Agreement, either through any complaint to any governmental agency or otherwise. You agree never to start any lawsuit or arbitration asserting any of the claims you are releasing in this Separation Agreement. You represent and
warrant that you have not initiated any complaint, charge, lawsuit or arbitration involving any of the claims you are releasing in this Separation Agreement. Should you apply for future employment with Employer, Employer has no obligation to
consider you for future employment. 
 (e) You represent and warrant that you have all necessary authority to enter into this Separation
Agreement (including, if you are married, on behalf of your marital community) and that you have not transferred any interest in any claims to your spouse or to any third party. 
 (f) This Separation Agreement does not affect your rights, if any, to receive pension plan benefits, medical plan benefits, unemployment compensation
benefits or workers’ compensation benefits. This Separation Agreement also does not affect your rights, if any, under agreements, bylaw provisions, insurance or otherwise, to be indemnified, defended or held harmless in connection with claims
that may be asserted against you by third parties. 
 (g) You understand that you are releasing potentially unknown claims, and that you have
limited knowledge with respect to some of the claims being released. You acknowledge that there is a risk that, after signing this Separation Agreement, you may learn information that might have affected your decision to enter into this Separation
Agreement. You assume this risk and all other risks of any mistake in entering into this Separation Agreement. You agree that this release is fairly and knowingly made. 
 (h) You are giving up all rights and claims of any kind, known or unknown, except for the rights specifically given to you in this Separation Agreement. 
 8. No Admission of Liability. Neither this Separation Agreement nor the payments made under this Separation Agreement are an admission of
liability or wrongdoing by Employer. 

 9. Employer Materials. You represent and warrant that you have, or no later than the Separation
Date will have, returned all keys, credit cards, documents and other materials that belong to us, in accordance with Section 8(g) of the Employment Agreement, which is incorporated herein by reference. 
 10. Nondisclosure Agreement. You will comply with the covenant regarding confidential information in Section 9(a) of the Employment
Agreement, which covenant is incorporated herein by reference. 
 11. No Disparagement. You may not disparage Employer or
Employer’s business or products, and may not encourage any third parties to sue Employer. 
 12. Cooperation Regarding Other
Claims. If any claim is asserted by or against Employer as to which you have relevant knowledge, you will reasonably cooperate with us in the prosecution or defense of that claim, including by providing truthful information and testimony as
reasonably requested by us. 
 13. Nonsolicitation; No interference. You will comply with Sections 9(b) and (c) of the Employment
Agreement, incorporated herein by reference, and Employer will have the right to enforce those provisions under the terms of Section 9(d) of the Employment Agreement, incorporated herein by reference. After the restrictive periods in
Section 9(b) and 9(c) of the Employment Agreement, you will not, apart from good faith competition, interfere with Employer’s relationships with customers, employees, vendors, or others. 
 14. Independent Legal Counsel. You are advised and encouraged to consult with an attorney before signing this Separation Agreement. You
acknowledge that you have had an adequate opportunity to do so. 
 15. Consideration Period. You have 21 days from the date this
Separation Agreement is given to you to consider this Separation Agreement before signing it. You may use as much or as little of this 21-day period as you wish before signing. If you do not sign and return this Separation Agreement within this
21-day period, you will not be eligible to receive the benefits described in this Separation Agreement. 
 16. Revocation Period and Effective Date. You have 7 calendar days after signing this Separation Agreement to revoke it. To revoke this Separation Agreement after signing it, you must deliver a written notice
of revocation to Employer’s President before the 7-day period expires. This Separation Agreement shall not become effective until the 8th
calendar day after you sign it. If you revoke this Separation Agreement it will not become effective or enforceable and you will not be entitled to the benefits described in this Separation Agreement. 
 17. Governing Law. This Separation Agreement is governed by the laws of the State of Washington that apply to contracts executed and to be
performed entirely within the State of Washington. 
 18. Dispute Resolution. 
 (a) Arbitration. Any dispute arising under this agreement shall be settled by final, binding, private arbitration in Cowlitz County,
Washington, unless the arbitrator is unwilling to travel to Cowlitz County, in which case the arbitration will be held in Seattle, Washington. This includes disputes about the meaning of the agreement and performance under the agreement. The
arbitration will be conducted by Judicial Dispute Resolution LLC with the arbitrator appointed and the arbitration conducted in accordance with Judicial Dispute Resolution rules and procedures. The arbitrator will have full authority 

  

 6 

 
to determine all issues, including arbitrability. The arbitrator’s award may be reduced to final judgment in Cowlitz County Superior
Court. Each party shall bear its own costs in connection with the arbitration and shall share equally the fees and expenses of the arbitrator, except that the arbitrator may award the prevailing party fees and costs. Notwithstanding the foregoing,
an aggrieved party may seek a temporary restraining order or preliminary injunction in Cowlitz County Superior Court to preserve the status quo during the arbitration proceeding, provided however, that the party seeking relief agrees that ultimate
resolution of the dispute will still be determined through arbitration and not through court process. The filing of the court action for injunctive relief shall not hinder or delay the arbitration process. 
 (b) Expenses/Attorneys’ Fees. The prevailing party shall be awarded all costs and expenses of the proceeding, including but not limited to,
attorneys’ fees, filing and service fees, witness fees and arbitrator’s fees. If arbitration is commenced, the arbitrator will have full authority and complete discretion to determine the “prevailing party” and the amount of
costs and expenses to be awarded. 
 19. Saving Provision. If any part of this Separation Agreement is held to be unenforceable, it
shall not affect any other part. If any part of this Separation Agreement is held to be unenforceable as written, it shall be enforced to the maximum extent allowed by applicable law. 
 20. Final and Complete Agreement. Except for the Employment Agreement to the extent it is expressly incorporated herein by reference, this
Separation Agreement is the final and complete expression of all agreements between us on all subjects and supersedes and replaces all prior discussions, representations, agreements, policies and practices. You acknowledge you are not signing this
Separation Agreement relying on anything not set out herein. 
  

									
	COWLITZ BANCORPORATION	 		 	COWLITZ BANK
					
	By:	 	 	 		 	By:	 	 
	Title:	 	 	 		 	Title:	 	 

 I, the undersigned, having been advised to consult with an attorney, hereby agree to be bound by this
Separation Agreement and confirm that I have read and understood each part of it. 
  

	
	
	  
	Gerald L. Brickey
	  
	DateManufacturing and Supply Agreement dated as of January 9, 2008

 Exhibit 10.16 
 Manufacturing and Supply Agreement: 
 Peptisyntha for Helix BioMedix, Inc. 
 This Manufacturing and Supply Agreement (the “Agreement”) is made as of January 9, 2008 (the “Effective Date”) by and between
Helix BioMedix, Inc., a Delaware corporation, its principal offices being located at 22118 20th Ave. SE, Suite 204, Bothell, WA 98021 (“Helix”) and Peptisyntha, Inc., a Delaware corporation, its principal offices being located at
20910 Higgins Court, Torrance, CA 90501 (“Peptisyntha”). 
 AGREEMENT 
 In consideration of the mutual covenants, promises, and conditions set forth below, the parties, intending to be bound, agree as follows: 
  

	1.	Definitions. The following capitalized terms when used in this Agreement shall have the respective meanings set forth below. 

  

	 	a.	“Bill of Material” shall mean any materials and components lists and related instructions and information provided by Helix to Peptisyntha and concerning components
required or preferred for the manufacture of a Peptide by Peptisyntha pursuant to this Agreement. 

  

	 	b.	“Disclosing Party” shall have the meaning stated in Section 10 hereof. 

  

	 	c.	“Effective Date” shall have the meaning stated in the preamble of this Agreement. 

  

	 	d.	“Intellectual Property” shall mean trade secrets, ideas, inventions, designs, developments, devices, methods or processes (whether patented or able to be patented
and whether or not reduced to practice) and all patents and patent applications related thereto; copyrightable works and mask works (whether or not registered); trademarks, service marks and trade dress; and all registrations and applications for
registration related thereto; and all other intellectual or industrial property rights of any sort. 

  

	 	e.	“Losses” shall mean any and all damages, liabilities, costs and expenses (including reasonable attorneys fees and expenses), and amounts paid in settlement.

  

	 	f.	“Peptides” shall mean the amino acid sequences identified in Exhibit A hereto, as may be amended from time to time by agreement of the parties.

  

	 	g.	“Proprietary Information” shall have the meaning stated in Section 10. 

  

	 	h.	“Recipient” shall have the meaning stated in Section 10. 

  

	 	i.	“Specifications” shall mean the requirements for Peptides set forth in Exhibit B, as may be amended from time to time by agreement of the parties.

  

	2.	Supply Obligations. During the Term of this Agreement, Peptisyntha shall manufacture for Helix its requirements for the Peptides (including the requirements of Helix’s
licensees of Peptides), subject to and in accordance with the terms and conditions set forth in this Agreement, including without limitation the Specifications. 

 Confidential treatment has been requested for portions of Exhibit A. This exhibit omits the information subject to the confidential treatment request. Omissions are designated as ***. A complete version of
this exhibit has been filed separately with the Securities and Exchange Commission. 

	3.	Document Control and Process. 

  

	 	a.	Document Control. All Specifications, Bills of Material and other documents provided to Peptisyntha pursuant to this Agreement, including without limitation all
modifications, revisions, updates, supplements and amendments thereto, will be maintained by Peptisyntha in an orderly manner promptly upon receipt thereof. 

  

	 	b.	Manufacturing. Peptisyntha will maintain records pertaining to the manufacture and quality control of the Peptides. 

  

	 	c.	Design Changes. Helix shall be responsible for providing Peptisyntha with any desired modifications, updates or other changes to the Specifications, which shall be processed
by Peptisyntha in accordance with the foregoing provisions of this Section 3. If a change results in an increase in Peptisyntha’s cost of production, Peptisyntha will provide a quote to Helix for revised pricing associated with the change
and substantiating such increased cost of production. 

  

	 	d.	Testing and Quality; Certificate of Analysis. Peptisyntha will establish and perform customary quality assurance and quality control procedures relating to its obligations
hereunder. Helix may perform testing procedures at its discretion and as may be agreed by the parties. Procedures to be performed by Peptisyntha will be incorporated into its manufacturing quality system. Peptisyntha will provide to Helix a
certificate of analysis promptly upon completion of production of each Peptide lot, which will include customary data, including without limitation Peptide name (not the sequence), lot number, quantity, purity level determined by HPLC/UV with
chromatogram included, mass analysis by HPLC co-eluent analysis using a previously characterized peptide standard, counter ion, color, formula weight, and release date. Any comments related to any unusual observations should also be included. No
Peptide from any lot will be shipped by Peptisyntha to a Helix licensee until Helix has approved the associated certificate of analysis. 

  

	 	e.	Helix Accessibility. Upon reasonable prior notice, Helix shall have access to the areas of any Peptisyntha facility where Peptides are being manufactured or stored or where
parts and materials are being processed or stored at all times during normal business hours for purposes of quality inspection, verification of manufacturing procedures and other legitimate purposes. Without limiting the generality of the foregoing,
Helix may inspect a sample or the entirety of any Peptide lot produced by Peptisyntha upon Helix’s request. Upon request by Helix, Peptide samples will be shipped to Helix for inspection. 

  

	 	f.	Regulatory Requirements. Helix will be responsible for compliance with all applicable regulatory and related matters which may require regulatory agency notification
including FDA IND / NDA, and other agency notifications. Peptisyntha shall provide such assistance and cooperation as Helix shall reasonably request, including without limitation the provision of relevant manufacturing records. Each party shall
obtain and bear costs associated with all domestic and foreign governmental licenses, permits and approvals required for such party’s performance under this Agreement. Without limiting the generality of the foregoing: (i) Helix shall be
responsible for complying with all applicable foreign and U.S. federal, state and local laws, rules, regulations and orders and for obtaining all applicable U.S. FDA and other governmental agency product approvals and applicable foreign agency
approval in each case relating to the sale of products containing its Peptides; and (ii) Peptisyntha shall be responsible for complying with all foreign and U.S. federal, state and local laws, rules, regulations and orders applicable to its
performance and obligations hereunder. 

  

					
	*** Confidential treatment requested	 	2	 	

	 	g.	Labeling. Peptisyntha will label Peptide according to specifications and label copy provided by Helix. Unless otherwise notified by Helix, Peptisyntha will use the label copy
attached hereto as Exhibit C for all Peptides supplied hereunder. Helix will be solely responsible for liabilities arising from Peptide labeling in accordance with its instructions (including without limitation claims of misbranding or
unapproved indications) and will indemnify Peptisyntha as set forth in Section 11. 

  

	 	h.	Product Recall. In the event of a product recall conducted by Helix, Peptisyntha shall cooperate with Helix recall investigations, including providing manufacturing-related
records as they relate to the recall. Peptisyntha and Helix shall cooperate in jointly assessing the root cause of a product recall. If Helix is solely responsible for defect giving rise to the recall, Helix will reimburse Peptisyntha for all
reasonable costs and expenses incurred by Peptisyntha directly as a result of its cooperation in such recall. If Peptisyntha is solely responsible for the defect giving rise to the recall, Helix will not reimburse Peptisyntha for expenses incurred
in providing replacement components. This section will not be deemed to limit either party’s obligations under Section 11 (Indemnification). 

  

	4.	Cost Reductions. Peptisyntha and Helix agree to seek ways to reduce the cost of manufacturing Peptides by methods such as obtaining alternate sources of materials and
improved synthesis or test methods. Peptisyntha and Helix agree to meet at least every six (6) months to identify cost reduction opportunities. 

  

	5.	Orders, Changes and Cancellation. 

  

	 	a.	Orders. Peptisyntha shall initiate manufacturing of Peptide upon receipt of a written production order (“Production Order”) from Helix. Production Orders
will specify which Helix licensees may set up a direct account with Peptisyntha and purchase Peptide synthesized under that Production Order; no party other than Helix and such licensees may obtain Peptides from Peptisyntha. Peptisyntha will use
best commercial efforts to complete production of Peptide under a Production Order (or, at Peptisyntha’s option, prepare and store resin sufficient for such production) within 8 to 12 weeks of receiving a Production Order from Helix. Peptide
produced under a Production Order will not be shipped by Peptisyntha until Peptisyntha receives a purchase order (“Purchase Order”) from Helix or a licensee approved by Helix with respect to the applicable Production Order.
Peptisyntha will provide a delivery schedule upon receipt of the Purchase Order, and will use best commercial efforts to make delivery with respect to Purchase Orders made under completed Production Orders within 3 to 4 weeks of their receipt. If
any Peptide inventory remains un-purchased with Peptisyntha 12 months after completion of production under a Production Order (or another period pre-negotiated between Helix and Peptisyntha), Helix will purchase such remaining inventory. Peptisyntha
will not be obligated to satisfy more than one Production Order at a time, but will consider the possibility depending on its current production schedule. 

  

	 	b.	Order Changes. The terms of any Production Order or Purchase Order may be adjusted by mutual written agreement of Peptisyntha and Helix (or Peptisyntha and an authorized
licensee of Helix with respect to a Purchase Order placed by a licensee). Peptisyntha shall use its best commercial efforts to accommodate any changes requested by Helix or such authorized licensee. 

  

					
	*** Confidential treatment requested	 	3	 	

	 	c.	Cancellation. Helix may cancel any Production Order; provided that in the event Helix cancels a Production Order, Peptisyntha shall stop any work-in-process and Helix
shall purchase from Peptisyntha all finished goods inventory, work in process (including full reimbursement of labor and other related costs to Peptisyntha) and raw material (including full reimbursement of all related costs to Peptisyntha) for
which title has not passed to Helix. 

  

	 	d.	Materials Inventory. Peptisyntha shall be authorized to purchase inventory not otherwise normally stocked by Peptisyntha (“Special Inventory”) and maintain
levels needed to satisfy outstanding Production Orders and Production Orders anticipated by Helix as to which Helix notifies Peptisyntha. Such material inventory schedule shall be based on material lead-times, reasonable inventory on-hand stocking
levels and minimum purchase quantities. Any Special Inventory in excess of such amounts may be obtained by Peptisyntha only upon written authorization from Helix. Upon termination or cancellation of this Agreement, Helix shall purchase from
Peptisyntha at Peptisyntha’s burdened cost, any unused Special Inventory obtained by Peptisyntha in accordance herewith. 

  

	 	e.	Obsolete Inventory. Helix agrees to purchase from Peptisyntha, at burdened cost, any inventory purchased by Peptisyntha in reliance on Production Orders or as Special
Inventory obtained in accordance herewith, which inventory is rendered obsolete due to a change to the Specifications. Peptisyntha shall, however, first use reasonable efforts to use or return any such inventory, and Helix agrees to pay for the
restocking charges, shipping and similar out-of-pocket costs borne by Peptisyntha as applicable. 

  

	 	f.	Notice of Licensee Purchase Order. Peptisyntha will notify Helix within five (5) business days after any Helix licensee places a Purchase Order for any Peptide (and
within five (5) business days after any such Purchase Order is changed), such notice to include the identity and quantity of the Peptide(s) thereunder. 

  

	6.	Packaging, Shipping and Delivery. Peptisyntha shall ship the Peptides in accordance with packaging and shipping instructions provided by Helix or its authorized licensee.
Peptides shall be delivered by Peptisyntha F.O.B. Helix’s or its licensee’s facility (as applicable). 

  

	7.	Payment. 

  

	 	a.	Invoice. Peptisyntha will invoice Helix for Purchase Orders placed by Helix, and will invoice the applicable authorized licensee for Purchase Orders placed by a licensee.
Helix shall pay invoices submitted to Helix in accordance with this Section 7(a) within 30 days of receipt, provided that Peptide meets the Specifications. Notwithstanding any other provision of this Agreement, Helix shall have no
liability for payment with respect to Purchase Orders placed by Helix licensees. Peptisyntha will also invoice Helix for any inventory that remains un-purchased with Peptisyntha 12 months after completion of production under a Production Order (or
another period pre-negotiated between Helix and Peptisyntha). 

  

	 	b.	Pricing. Prices for Peptide shall be as set forth in Exhibit A during the Term hereof, whether purchased by Helix or a licensee of Helix. Peptide prices are exclusive
of taxes, shipping and insurance. Charges for taxes, shipping and insurance (to the extent applicable) shall be separately stated on Peptisyntha’s invoices. Any increase in pricing during the Term must be attributable to a commensurate increase
in direct production costs realized by Peptisyntha and documented as such. In no event shall the price of any Peptide be increased by more that 10% during the Term of this Agreement. 

  

					
	*** Confidential treatment requested	 	4	 	

	8.	Warranty. 

  

	 	a.	Specification Warranty. Peptisyntha warrants that the Peptides will meet the Specifications. 

  

	 	b.	PEPTISYNTHA EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE AND MERCHANTABILITY. 

 

	9.	Intellectual Property. 

  

	 	a.	All Intellectual Property developed during the Term by either party, in the performance of this Agreement or making use of Proprietary Information of the other party, that pertains
to the synthesis and manufacture of Peptides, shall be owned by Peptisyntha. All Intellectual Property developed during the Term by either party, in the performance of this Agreement or making use of Proprietary Information of the other party, that
pertains to Peptide sequences or Peptide activities, or the sequences or activities of molecules other than the Peptides, shall be owned by Helix. Each party hereby makes any assignments necessary to effect the ownership provisions set forth in this
Section 9(a), and the assigning party agrees to assist the other party (at the other party’s expense) in every proper way to evidence, record and perfect such assignments. This Section 9(a) shall not be deemed to affect the relative
rights of the parties with respect to Intellectual Property existing as of the Effective Date. 

  

	10.	Confidentiality. 

  

	 	a.	General Obligation. All information provided by one party (the “Disclosing Party”) to the other party (the “Recipient”) shall be governed by
this Section 10. 

  

	 	b.	Proprietary Information. As used in this Agreement, the term “Proprietary Information” shall mean all trade secrets or confidential or proprietary
information designated as such in writing by the Disclosing Party, whether by letter or by the use of an appropriate proprietary stamp or legend. To avoid misunderstanding, anything to be treated as Proprietary Information should be supplied in
written form, or put into a written summary within thirty days after its first verbal or visual presentation to Recipient, and be clearly marked. “Proprietary Information” also includes information disclosed by either party to the other
party before the Effective Date, where such disclosure was made subject to an obligation of confidentiality on the part of the Recipient. 

  

	 	c.	 Disclosure. The Recipient shall hold in confidence, and shall not disclose to any person outside its organization, any Proprietary Information, regardless of
any termination or expiration of this Agreement, for a period of five (5) years from the date of disclosure, or, with respect to Proprietary Information disclosed before the Effective Date, for five (5) years from the Effective Date. The
Recipient shall use such Proprietary Information only for the purposes of fulfilling its obligations hereunder and shall not use or exploit such Proprietary Information for any other purpose or for its own benefit or the benefit of another without
the prior written consent of the Disclosing Party. The Recipient shall disclose Proprietary Information received by it under this Agreement only to persons 

  

					
	*** Confidential treatment requested	 	5	 	

	 	 
within its organization who have a need to know such Proprietary Information in the course of the performance of their duties and who are bound to protect
the confidentiality of such Proprietary Information. Notwithstanding the foregoing, Peptisyntha may disclose Proprietary Information to its affiliates on a need to know basis, and shall be responsible for compliance by such affiliates with the terms
of this Agreement. 

  

	 	d.	Limitation on Obligations. The obligations of the Recipient specified in this Section 10 above shall not apply, and the Recipient shall have no further obligations, with
respect to any Proprietary Information to the extent that such Proprietary Information: (i) is generally known to the public at the time of disclosure or becomes generally known through no wrongful act on the part of the Recipient; (ii) is
in the Recipient’s possession at the time of disclosure otherwise than as a result of Recipient’s breach of any legal obligation; (iii) becomes known to the Recipient through disclosure by sources other than the Disclosing Party
having the legal right to disclose such Proprietary Information (iv) is independently developed by the Recipient without reference to or reliance upon the Proprietary Information; or (v) is required to be disclosed by the Recipient under a
court order, provided that the Recipient provides prompt written notice of such order to the Disclosing Party, makes diligent efforts to avoid and/or minimize the extent of such disclosure, and allows the Disclosing Party to participate in
the proceeding. 

  

	 	e.	Ownership of Proprietary Information. The Recipient agrees that the Disclosing Party is and shall remain the exclusive owner of Proprietary Information and all Intellectual
Property rights embodied therein. 

  

	 	f.	Return of Documents. The Recipient shall, upon the request of the Disclosing Party, return to the Disclosing Party or destroy (at the Disclosing Party’s option) all
drawings, documents and other tangible manifestations of Proprietary Information received by the Recipient pursuant to this Agreement (and all copies and reproductions thereof). 

  

	11.	Indemnification. 

  

	 	a.	Indemnification. Helix shall indemnify, defend and hold harmless Peptisyntha from and against any Losses arising out of or relating to a claim brought by a third party
against Peptisyntha only to the extent that such Losses are caused by (i) a defect in the design of any Peptides by Helix or improper labeling as directed by Helix to Peptisyntha, (ii) a breach of the terms of this Agreement by Helix, or
(iii) the gross negligence or intentional misconduct of Helix. Peptisyntha shall indemnify, defend and hold harmless Helix from and against any Losses arising out of or relating to a claim brought by a third party against Helix only to the
extent that such Losses are caused by (i) a defect as a result of the Peptide being produced outside of the Specifications, (ii) any other breach of the terms of this Agreement by Peptisyntha, or (iii) Peptisyntha’s gross
negligence or intentional misconduct. 

  

	 	b.	 Indemnification Procedure. A party claiming indemnification under this Section 11 (an “Indemnified Party”) shall provide prompt written
notice to the other party (the “Indemnifying Party”) of any and all notices, claims, demands, pleadings, and other facts or circumstances that may, in the Indemnified Party’s reasonable judgment, be likely to result in a claim
for indemnification. The Indemnified Party’s failure to provide such prompt written notice shall reduce the indemnification obligation of the Indemnifying Party to the extent that such failure resulted in demonstrable prejudice to the
Indemnifying Party. The Indemnified Party shall promptly tender defense of any 

  

					
	*** Confidential treatment requested	 	6	 	

	 	 
litigation or other formal dispute to the Indemnifying Party, and the Indemnifying Party shall select counsel of its choice, reasonably acceptable to the
Indemnified Party for such litigation or dispute. The Indemnified Party shall cooperate completely with the Indemnifying Party, including without limitation providing timely responses to all discovery requests and providing expert and factual
witnesses as necessary or desirable. The Indemnifying Party may not settle such action without first obtaining the written consent of the Indemnified Party, which consent will not be unreasonably withheld or delayed, except for settlements solely
covering monetary matters for which the Indemnifying Party acknowledges responsibility for payment. The Indemnifying Party shall permit the Indemnified Party (at the Indemnified Party’s sole cost and expense) to participate in such settlement
or defense through counsel chosen by the Indemnified Party. 

  

	 	c.	Insurance. Each party shall maintain products and general liability insurance in an amount not less than $5,000,000. Any amounts paid under such insurance policies by either
party’s insurer shall reduce the indemnification obligation of the Indemnified Party with respect to a particular claim. 

  

	12.	Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES, INCLUDING, BUT NOT LIMITED TO, DAMAGE TO
PROPERTY, FOR LOSS OF USE, LOSS OF TIME, OR LOSS OF PROFITS OR INCOME. 

  

	13.	Integration. This Agreement constitutes the complete and exclusive statement of the terms of the agreement between Peptisyntha and Helix and supersedes all prior and
contemporaneous agreements including purchase orders and undertakings of Peptisyntha and Helix with respect to the subject matter hereof. 

  

	14.	Term and Termination. 

  

	 	a.	Initial Term and Renewal Term. Unless sooner terminated in accordance with Section 14(b) or (c), the initial term of this Agreement shall be two (2) years and
thereafter this Agreement shall automatically renew for successive one year periods (such initial term and renewal terms collectively referred to herein as the “Term”). 

  

	 	b.	Termination For Cause. The Term of this Agreement shall terminate: (i) automatically, if one of the parties fails to perform any material obligations hereunder, and such
material obligations remain uncured sixty (60) days following the date that the other party delivers to the defaulting party written notice describing such performance failures; (ii) immediately upon notice by either party if the other
party shall file for liquidation, bankruptcy, reorganization, compulsory composition, dissolution, or if the other party has entered into liquidation, bankruptcy, reorganization, compulsory composition or dissolution, or if the other party is
generally not paying its debts as they become due (unless such debts are the subject of a bona fide dispute) or (iii) immediately upon notice if Peptisyntha is unable to maintain its ISO certification or other necessary registrations.

  

	 	c.	Effect of Termination/Survival. Upon expiration of the Term of this Agreement or termination hereof, Peptisyntha shall cease accepting Purchase Orders from Helix Licensees
and neither party shall have any obligations to the other, except obligations hereunder accrued to the date of termination. Additionally, Helix shall have the option of placing one additional Production Order for any or all Peptides, provided that
such Production Order is accompanied by a Purchase Order for the full quantity. The provisions set forth in Sections 1, 9 through 14 and 16 through 25 shall survive any termination hereof indefinitely. 

  

					
	*** Confidential treatment requested	 	7	 	

	15.	Compliance with Laws. Each party shall comply with all domestic and foreign laws, rules, regulations and orders applicable to such party’s performance under this
Agreement. 

  

	16.	Assignment and Delegation. This Agreement cannot be assigned nor is the performance of the duties delegable by either party without the written consent of the other party;
provided, however, that this Agreement may be assigned by either party to a purchaser of substantially all of such party’s assets relating to the Peptides, or to a successor in interest by merger or corporate reorganization.

  

	17.	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflicts of law
provisions thereof. 

  

	18.	Relationship of Parties. The relationship of Helix and Peptisyntha is that of purchaser and seller/manufacturer, respectively, of goods. Nothing in this Agreement is intended
to, or shall be deemed to, constitute a partnership, joint venture, agency, or a transfer of any intellectual property of either party, and neither party hereto shall be authorized to act in the name of the other or enter into any contract or other
agreement which binds the other. 

  

	19.	Enforceability. If any of the provisions of this Agreement, or portions thereof, are found to be invalid by any court of competent jurisdiction the remainder of this
Agreement shall nevertheless remain in full force and effect. 

  

	20.	Force Majeure. Peptisyntha shall use its commercially reasonable best efforts to notify Helix at least thirty (30) days in advance of any planned holidays or shutdowns,
but neither Helix nor Peptisyntha shall be liable for any failure to perform obligations under this Agreement (other than the obligation to make timely payment of amounts due hereunder) if prevented so by a cause beyond their control and without the
fault or negligence of the defaulting party. Without limiting the generality of the foregoing, such causes include acts of God, fires, floods, storms, epidemics, earthquakes, riots, civil disobedience, wars or war operations, or restraint of
government. 

  

	21.	Amendment. This Agreement may not be amended except in a written amendment signed by each of the parties. Additional or different terms contained in purchase orders or order
acknowledgments or similar forms shall not be effective unless signed by both parties with reference to this Agreement. 

  

	22.	Dispute Resolution. Consent to Arbitration and Venue. Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by
arbitration conducted in Wilmington, Delaware and administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrator(s) may be entered in any court having
jurisdiction thereof. Notwithstanding the foregoing, either party may, without waiving any remedy under this Agreement, seek from any court having jurisdiction thereof any interim or provisional relief that is necessary to protect the rights or
property of that party from immediate and irreparable injury, loss, or damage. 

  

	23.	Attorneys’ Fees. If either party brings an action to enforce any rights arising out of or relating to this Agreement, the prevailing party in such action shall be
entitled to recover from the losing party its reasonable fees, costs and expenses in connection with such action, including reasonable attorneys’ fees. 

  

					
	*** Confidential treatment requested	 	8	 	

	24.	Notices. All notices, requests, and other communications hereunder shall be in writing. Any notice, request, or other communication hereunder shall be deemed duly given:
(a) when delivered personally to the recipient; (b) 1 business day after being sent to the recipient by reputable overnight courier service (charges prepaid); (c) 1 business day after being sent to the recipient by fax or email; or
(d) 4 business days after being mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid, and addressed to the intended recipient as set forth below: 

  

			
	 If to Peptisyntha:
	 	If to Helix:
		
	 Address:
  
 20910 Higgins Court
 Torrance, CA 90501
  
 Fax: 310-782-7352
  
 Email:
shima.joshi@solvay.com
  
 Attn: Dr. Shima
Joshi, VP Operations
	 	 Address:
  
 22118 20th Avenue SE, Suite 204
 Bothell, WA 98021
  
 Fax: 425-806-2999
  
 Email: dkirske@helixbiomedix.com
  
 Attn: David H. Kirske, VP and CFO

 Either party may change the address or other contact information to which notices, requests, and other
communications hereunder are to be delivered by giving the other party notice in the manner set forth herein. 
  

	25.	No Waiver. No waiver of any breach of any provision of this Agreement will constitute a waiver of any prior, concurrent or subsequent breach of the same or any other
provisions hereof, and no waiver shall be effective unless made in writing and signed by an authorized representative of the waiving party. 

 [SIGNATURE PAGE FOLLOWS] 
  

					
	*** Confidential treatment requested	 	9	 	

 IN WITNESS WHEREOF, the authorized representatives signing below have entered into this Manufacturing and Supply
Agreement on behalf of the parties as of the Effective Date. 
  

									
	PEPTISYNTHA, INC.	 		 	HELIX BIOMEDIX, INC.
					
	By:	 	 	 		 	By:	 	 
					
	Name:	 	 	 		 	Name:	 	 
					
	Title:	 	 	 		 	Title:	 	 

 [SIGNATURE PAGE TO MANUFACTURING AND SUPPLY AGREEMENT] 

 Exhibit A: Peptides and Pricing 
  

							
	 	  	 Peptide Name
	  	Sequence	 	Price($)
per
kilogram
				
		  	HB 168	  	***	 	***
				
		  	HB 168 PAL	  	***	 	***
				
	 (a)
	  	HB 64	  	***	 	***
				
		  	HB 1423	  	***	 	***
				
		  	HB 1422	  	***	 	***
				
		  	Minimum quantity per Production Order is 1 kg for each Peptide	  		 	
				
		  	The price per kg of the indicated Peptides will be increased by ***% per kg under any Production Order for less than *** kg.	  		 	

 Exhibit B 
 Specifications 
 1. Purity level >80% determined by HPLC/UV. 
 2. Peptide identity confirmed by HPLC co-eluent analysis with previously characterized peptide standard. 
 3. The counter ion must be TFA. 
 4. Appearance of the Peptide must be white or off white. 

 Exhibit C 
 Label Copy 
  

			
	Store desiccated at 2-8° Centigrade.	 	Manufactured for Helix BioMedix, Inc.

 (Specific Peptide Info added here) 
 Warning: May be harmful if swallowed, inhaled or absorbed through skin and respiratory tract. May cause irritation to skin and eyes. Bioactive peptide. Systemic
toxicological properties unknown. For topical cosmetic formulation use only. Not GMP qualified for diagnostic or drug use. Additional information available on Material Safety Data Sheet. 
 Helix BioMedix, Inc. 22118 20th Ave. SE, Suite 204, Bothell, WA 98021 Tel: 425-402-8400 Fax: 425-806-1299

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]